From: Drug shortages in low- and middle-income countries: Colombia as a case study
All cases, closed and active (N = 229) | Active cases (N = 173) | ||||||
---|---|---|---|---|---|---|---|
No. | Chemical subgroup | n | % | No. | Chemical subgroup | n | % |
1 | Antidotes | 10 | 4.4% | 1 | Antidotes | 9 | 5.2% |
2 | Amides | 8 | 3.5% | 2 | Various alimentary tract and metabolism prods | 6 | 3.5% |
3 | Enzymes | 6 | 2.6% | 3 | Enzymes | 5 | 2.9% |
Various alimentary tract and metabolism prods | 6 | 2.6% | Heparin group | 5 | 2.9% | ||
Amides | 5 | 2.9% | |||||
4 | Amino acids and derivatives | 5 | 2.2% | 4 | Adrenergic and dopaminergic agents | 4 | 2.3% |
Heparin group | 5 | 2.2% | Other quaternary ammonium compounds | 4 | 2.3% | ||
Adrenergic and dopaminergic agents | 5 | 2.2% | Other general anesthetics | 4 | 2.3% | ||
Other general anesthetics | 5 | 2.2% | Medical gases | 4 | 2.3% | ||
5 | Other quaternary ammonium compounds | 4 | 1.7% | 5 | Amino acids and derivatives | 3 | 1.7% |
Medical gases | 4 | 1.7% | Other antiseptics and disinfectants | 3 | 1.7% | ||
Immune sera | 3 | 1.7% | |||||
Other antineoplastic agents | 3 | 1.7% |